Rapid and Intensive Medication Optimization for Women Hospitalized with Heart Failure Comparing High-Intensity Care Versus Usual Care to Improve Outcomes
Led by IRCCS Policlinico S. Donato · Updated on 2026-10-16
368
Participants Needed
12
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether quickly and intensively adjusting heart failure medications in women can improve outcomes after hospital stays for heart failure. The study aims to find out if this high-intensity treatment reduces death or hospital readmissions within one year, if women benefit as much as men from full-dose therapy, and if this approach is safe and manageable for women. This phase IV trial is sponsored by IRCCS Policlinico San Donato and involves multiple centers in Italy.
Participants are randomly assigned to one of two groups a high-intensity care group that starts and increases all recommended heart failure drugs rapidly during hospitalization and early weeks after discharge, following the STRONG-HF protocol and a usual care group where medications are introduced and adjusted gradually according to doctors usual practice. The high-intensity group receives frequent clinical assessments and safety monitoring including vital signs, physical exams, and lab tests such as NT-proBNP and kidney function. Both groups have follow-up visits scheduled up to one year after randomization.
Women in the study will attend regular visits at multiple time points over 12 months, completing quality-of-life questionnaires and undergoing safety checks. Researchers will measure a combined outcome of death, heart failure readmission, or worsening symptoms within a year. They will also assess medication optimization, side effects, biomarker changes, and overall quality of life. The study monitors participants closely to evaluate the safety, tolerance, and feasibility of rapid medication optimization in women with heart failure.
CONDITIONS
Brief Title
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
Research Team
M
Massimo Piepoli, MD
G
Giovanna Landi, PharmD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Hospital admission within 72 hours before screening for acute heart failure with symptoms such as shortness of breath and lung congestion
Stable systolic blood pressure of at least 100 mmHg and heart rate of at least 60 bpm within 24 hours before randomization
Serum potassium level of 5.0 mEq/L or lower within 24 hours before randomization
Elevated NT-proBNP levels at screening and randomization indicating persistent congestion
For ejection fraction below 50%, less than half the optimal dose of certain heart failure medications must have been prescribed; for ejection fraction above 50%, less than half the optimal dose of specific medications applies
Signed informed consent to participate
You will not qualify if you...
Male patients
Age below 18 or above 85 years
Mechanical ventilation (excluding CPAP/BIPAP) within 24 hours before screening
Significant lung disease affecting breathing, or primary right heart failure conditions
Recent heart attack, unstable angina, cardiac surgery, device implantation, or interventions within specified timeframes before screening
Acute heart failure caused mainly by correctable conditions like severe arrhythmia, infection, anemia, pulmonary embolism, or COPD exacerbation
Uncorrected thyroid disease, active myocarditis, amyloid or hypertrophic obstructive cardiomyopathy
History of heart transplant or planned ventricular assist device
Significant heart valve problems except those caused by left heart enlargement
Active infection during hospitalization before randomization
Stroke or transient ischemic attack within 3 months before screening
Life-threatening liver disease or severe kidney disease or dialysis history
Serious psychiatric, neurological, or cancer conditions with life expectancy under 6 months
Recent participation in other heart failure trials or investigational drug/device studies
Discharge anticipated more than 14 days after admission or to long-term care
Inability to comply with study requirements due to medical, social, or financial reasons
Pregnant or nursing women
Allergy to study medications or components
Angioedema
Severe heart failure classified as NYHA class IV
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 12 months
Participants receive either rapid initiation and optimization of heart failure medications following the STRONG-HF protocol or usual care with gradual medication adjustments. Safety and medication effects are closely monitored during this period.
Visits at 2, 4, 6, 12, 24, 36, and 52 weeks with possible additional visits after medication adjustments
Follow-up
Duration - 12 months
Participants continue to be monitored for outcomes including death, heart failure readmission, symptom worsening, medication tolerance, and quality of life for up to one year after treatment begins.
Regular follow-up visits and questionnaires throughout the year
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 2 Study of 18F-mFBG PET Imaging
for Heart Failure Patients with Ischemic Cardiomyopathy
and Implantable Cardioverter-Defibrillators
Post-Discharge Counseling and Phone Follow-Up to Reduce Heart Failure Readmissions at Komfo Anokye Teaching Hospital
Myocardial Energetic Profiling Using 31P Magnetic Resonance Spectroscopy
and Prognostic Assessment Across Heart Failure and Cardiomyopathy Types
3D Imaging Study of Right Heart Function During Mechanical Pump Placement for Heart Failure
Evaluating Cardiac Fibrosis in Heart Failure Using 68Ga-FAPI PETCT Compared to MRI
A Pilot Study in Patients with HFrEF and HFpEF
Study of Vascular Function and Exercise Effects in Aging and Cardiovascular Diseases Including COPD and Pulmonary Hypertension
A Phase I Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Effects of Oral Doses of HRS-5765 in Healthy Adults Aged 18 to 65
Phase I Study Evaluating Safety and Pharmacokinetics of Single and Multiple Oral Doses of HRS-7156 in Healthy Adults
Optimizing Heart Failure and Chronic Kidney Disease Treatment in Elderly Patients Using Sodium Zirconium Cyclosilicate to Manage Potassium Levels
Danish Study Testing Coenzyme Q10 and Selenium Supplements to Reduce Hospitalization and Death in Heart Failure Patients
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Paul A Heidenreich, Biykem Bozkurt, David Aguilar...
Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Chris J Kapelios, Jonathan R Murrow, Thomas G Nührenberg...
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.
Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry.
Mitja Lainščak, Ivan Milinković, Marija Polovina...